TRON GROUP INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.512 USD | -14.67% |
|
-14.67% | -15.79% |
| 2022 | TRON Group Inc. Appoints James D. Talton as President, Secretary/Treasurer and Director | CI |
| 2022 | TRON Group Inc. Appoints James D. Talton as Chief Executive Officer | CI |
| Sales 2016 | 1.48M 116M | Sales 2017 | 1.48M 117M | Capitalization | 89.09M 7.02B |
|---|---|---|---|---|---|
| Net income 2016 | - 0 | Net income 2017 | - 0 | EV / Sales 2016 * | - |
| Net cash position 2016 * | - 0 | Net cash position 2017 * | - 0 | EV / Sales 2017 * | - |
| P/E ratio 2016 * |
-
| P/E ratio 2017 * |
-
| Employees | - |
| Yield 2016 * |
-
| Yield 2017 * |
-
| Free-Float | 1.1% |
More Fundamentals
* Assessed data
More news
| 1 day | -14.67% | ||
| 1 week | -14.67% | ||
| Current month | -14.67% | ||
| 1 month | -14.67% | ||
| 3 months | -14.67% | ||
| 6 months | -15.79% | ||
| Current year | -15.79% |
1 week
0.51
0.51
1 month
0.510.51
Current year
0.510.60
1 year
0.320.85
3 years
0.253.90
5 years
0.097.00
10 years
0.097.00
| Managers | Title | Age | Since |
|---|---|---|---|
Quoc Tuan Nguyen
CEO | Chief Executive Officer | - | - |
| Director/Board Member | 46 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 46 | - | |
Quoc Tuan Nguyen
CEO | Chief Executive Officer | - | - |
Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company. The Company is developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The Company is developing a clinical pipeline of oral, topical and injectable small molecule drug candidates to treat human cancer, central nervous system (CNS) disorders and infectious diseases. The pipeline includes 10 clinical-stage proprietary and partnered programs including Triapine, Ammonium Tetrathiomolybdate and Aza-TdC, targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3, targeting CNS; and Ramoplanin and NanoDOX, targeting infectious disease. Leveraging its expertise in nanoparticle and fine-particle formulations, the Company is focused on formulation development aimed at improving drug absorption and stability. Triapine is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity.
| 1st Jan change | Capi. | |
|---|---|---|
| -15.79% | 89.09M | |
| +7.52% | 113B | |
| +11.38% | 106B | |
| -12.64% | 22.22B | |
| +0.44% | 22.27B | |
| -4.18% | 19.43B | |
| -37.85% | 17.87B | |
| -8.58% | 17.24B | |
| +37.41% | 12.52B | |
| -23.95% | 8.34B |
- Stock Market
- Equities
- TGRP Stock
